Targeted Oncology Staff

During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.

During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.

During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Zofia Piotrowska, MD, MHS, discussed molecular testing for actionable mutations and recommended treatments for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed with participants their approach toward assessing and treating a patient with symptoms possibly indicating primary myelofibrosis.

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MBBS, discussed with participants the tolerability and optimal use of therapies for newly-diagnosed multiple myeloma.

During a Targeted Oncology case-based roundtable event, Natalie S. Callander, MD, discussed studies that support alternative combination regimens after early relapse on bortezomib, lenalidomide, and dexamethasone for multiple myeloma.

During a Targeted Oncology case-based roundtable event, Helen Moon, MD, discussed with participants their approaches to metastatic bladder cancer and immunotherapy in the switch maintenance setting.

During a Targeted Oncology case-based roundtable event, Ulka N. Vaishampayan, MBBS, discussed the frontline combination regimens available for a patient with favorable risk clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.

During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed the choice of bridging therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who may receive CAR (chimeric antigen receptor) T-cell therapy. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, discussed data supporting the use of ruxolitinib and what role it may play in improving long-term outcomes for patients with myelofibrosis. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Christopher R. Flowers, MD, MS, discussed with participants their experiences referring patients for chimeric antigen receptor T-cell therapy and using bridging therapy. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, J. Paul Monk, MD, discussed dosing and sequencing considerations for the use of cabazitaxel for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology Evolving Paradigms roundtable, Sara A. Hurvitz, MD, discussed elacestrant and other investigational agents for patients with breast cancer.

During a Targeted Oncology case-based roundtable event, Rami Komrokji, MD, and participants discussed when to start treatment for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.

During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.

Anti-CD38 monoclonal antibodies represent an important advance in the treatment of multiple myeloma, providing new effective options for patients with newly diagnosed and relapsed/refractory disease.

During a Targeted Oncology case-based roundtable event, Hana Safah, MD, discussed chronic graft-vs-host disease in terms of diagnosis, phases, risk assessment, and treatment options.

During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.

During a Targeted Oncology case-based roundtable event, Matthew Matasar, MD, MS, discussed the case of a patient with diffuse large B-cell lymphoma who relapsed 18 months following frontline combination therapy.

During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.

At a live virtual event, Priyanka Sharma, MD, discussed the treatment options for patients with metastatic breast cancer who develop triple-negative breast cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants their experiences with using cabazitaxel in patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.

After participating in a Case-Based Roundtable event led by Gavitt Woodward, MD, M. Sheila Donnelly, MD, spoke with Targeted Oncology about the patients with lung cancer she treats.

Shannon N. Westin, MD and a group of peers discussed key consideration when approaching management of a patient with ovarian cancer.